
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen Inc is positioned for significant growth, particularly with the anticipated launch of its PRGN-2012 product in the second half of 2025, supported by upgraded GMP facilities that enhance manufacturing capacity. The company projects risk-adjusted revenues for PRGN-2012 to reach $93 million in 2026, with an impressive increase to $969 million by 2033, driven by strong Phase 2 data and a solid understanding of the market's needs. Additionally, adjustments in their financial model, including a revised patient population forecast and an increased annual pricing estimate, further underscore a positive outlook for the company's financial performance in the coming years.
Bears say
Precigen Inc has faced challenges in its financial performance, reflected in growing operational losses that raise concerns regarding its business sustainability in the competitive biotechnology sector. The company's reliance on exclusive collaborations for revenue generation poses a risk, as any setbacks in securing or maintaining partnerships could significantly impact its revenue streams. Additionally, the fluctuating nature of technology access fees and royalties underscores the volatility in the company’s income, further contributing to a negative outlook.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares